These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22348365)

  • 101. Initiating a glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes mellitus.
    Gavin JR
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S16-21. PubMed ID: 22267299
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.
    MacCallum L
    Can J Diabetes; 2014 Oct; 38(5):334-43. PubMed ID: 25284697
    [TBL] [Abstract][Full Text] [Related]  

  • 105. [Management of diabetic kidney disease: a summary of European Recommendations 2015].
    Staszków M; Mieczkowski M
    Wiad Lek; 2016; 69(5):732-735. PubMed ID: 28033597
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Significance of Metformin Use in Diabetic Kidney Disease.
    Kawanami D; Takashi Y; Tanabe M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545901
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [Anti-diabetics and chronic kidney disease].
    Garofalo C; Iazzetta N; Camocardi A; Pacilio M; Iodice C; Minutolo R; De Nicola L; Conte G
    G Ital Nefrol; 2015; 32(5):. PubMed ID: 26480253
    [TBL] [Abstract][Full Text] [Related]  

  • 108. [[GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE – HOW TO CHOOSE HYPOGLYCEMIC AGENT]?].
    Baretić M; Lang VB
    Acta Med Croatica; 2016 Dec; 70(4-5):269-74. PubMed ID: 29087153
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.
    Schwartz S; Herman M
    Postgrad Med; 2015 Jun; 127(5):480-93. PubMed ID: 25913393
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 111. [Glucose lowering drugs in case of impaired renal function].
    Assink MA; Abrahams AC; Rookmaaker MB
    Ned Tijdschr Geneeskd; 2014; 158():A6907. PubMed ID: 24618238
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies.
    Chang W; Chen L; Hatch GM
    Biochem Cell Biol; 2015 Oct; 93(5):479-86. PubMed ID: 25607236
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Antidiabetic medications and polypharmacy.
    Peron EP; Ogbonna KC; Donohoe KL
    Clin Geriatr Med; 2015 Feb; 31(1):17-27, vii. PubMed ID: 25453298
    [TBL] [Abstract][Full Text] [Related]  

  • 114. [Rational hypoglycemic therapy - nephro-diabetologic view].
    Kosmalski M; Kurnatowska I
    Pol Merkur Lekarski; 2018 Aug; 45(266):81-88. PubMed ID: 30240375
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pleiotropic effects of anti-diabetic drugs: A comprehensive review.
    Nath M; Bhattacharjee K; Choudhury Y
    Eur J Pharmacol; 2020 Oct; 884():173349. PubMed ID: 32650008
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Emerging Targets in Type 2 Diabetes and Diabetic Complications.
    Demir S; Nawroth PP; Herzig S; Ekim Üstünel B
    Adv Sci (Weinh); 2021 Sep; 8(18):e2100275. PubMed ID: 34319011
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    de Vries JK; Levin A; Loud F; Adler A; Mayer G; Pena MJ
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):24-29. PubMed ID: 30294955
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Preoperative Patient Evaluation: Newer Hypoglycemic Agents.
    Villasenor M; Selzer AR
    Anesthesiol Clin; 2024 Mar; 42(1):41-52. PubMed ID: 38278591
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.
    Amin M; Suksomboon N
    Drug Saf; 2014 Nov; 37(11):903-19. PubMed ID: 25249046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 6.